Connect with us
DAPA Banner

Business

SThree buys 857,933 shares for employee benefit trust

Published

on

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Veteran QB Traded to Eagles in Surprise Move

Published

on

Andy Dalton

CHARLOTTE, N.C. — Veteran quarterback Andy Dalton, known as the “Red Rifle,” was traded from the Carolina Panthers to the Philadelphia Eagles on March 18, 2026, in exchange for a 2027 seventh-round draft pick, sources told ESPN’s Adam Schefter and other outlets. The deal came shortly after Carolina signed Kenny Pickett as backup to starter Bryce Young, making Dalton expendable despite his experience and mentorship role.

Andy Dalton
Andy Dalton

Dalton, 38, enters his 16th NFL season with the Eagles, where he is expected to serve as a reliable backup and veteran presence. The move caps an offseason of speculation about his future in Carolina, where he spent three seasons providing stability behind Young. Here are five essential facts about the longtime journeyman quarterback whose career spans multiple teams and highlights his durability and leadership.

1. Dalton’s storied career began with the Bengals and includes three Pro Bowls

Born Oct. 29, 1987, in Katy, Texas, Dalton starred at TCU, earning Mountain West Offensive Player of the Year honors twice and leading the Horned Frogs to significant wins, including over Wisconsin in the 2010 Rose Bowl. Selected by the Cincinnati Bengals in the second round (35th overall) of the 2011 NFL draft, he became a starter immediately, throwing for over 3,000 yards in each of his first three seasons — one of only 10 quarterbacks in league history to achieve that feat early in a career.

Dalton led the Bengals to five playoff appearances from 2011-2015, including two AFC North titles, and earned Pro Bowl nods in 2011, 2014 and 2015. He holds franchise records for touchdown passes (204), completions and 300-yard games. His 70 career wins with Cincinnati gave him the best winning percentage among Bengals quarterbacks with 25+ starts. After nine seasons in Cincinnati, Dalton moved to the Dallas Cowboys (2020), Chicago Bears (2021), New Orleans Saints (2022) and Carolina Panthers (2023-2025) before the Eagles trade.

Advertisement

2. He has been a reliable backup and mentor across multiple teams

Dalton’s journeyman status reflects his value as a veteran backup capable of stepping in with minimal drop-off. In 2025 with Carolina, he appeared in limited action, completing 25 of 37 passes for 293 yards, one touchdown and one interception in spot duty, posting an 89.1 passer rating. Over recent seasons, he maintained solid efficiency, often with passer ratings above 82 despite limited starts.

He has thrown for over 39,000 career yards and 254 touchdowns, ranking among active quarterbacks in several categories. Known for his poise and preparation, Dalton has mentored young passers like Bryce Young in Carolina, offering guidance on film study, mechanics and leadership. His low-turnover style and experience in high-pressure situations make him attractive to teams needing depth.

3. The Panthers trade frees cap space and aligns with youth movement

Advertisement

Carolina signed Dalton to a two-year extension in 2025, but general manager Dan Morgan signaled interest in developing a younger backup behind Young. With Pickett now in place on a one-year deal worth up to $7.5 million, the Panthers traded Dalton for minimal return — a future seventh-rounder — to clear approximately $2 million in guaranteed salary and avoid dead cap hits. The move reflects Carolina’s focus on long-term growth around Young rather than retaining a veteran in a diminished role.

Dalton was open to exploring options, and the low-cost trade provided mutual benefit: Philadelphia gains a seasoned arm for depth behind their starter, while Carolina sheds salary without major draft capital loss.

4. Dalton joins the Eagles as insurance and leadership in the locker room

The Eagles, coming off a strong 2025 campaign, added Dalton to bolster quarterback depth amid ongoing discussions about their starter’s future. At 6-foot-2 and 220 pounds, Dalton brings arm strength, accuracy on intermediate throws and experience in varied offenses. His arrival provides a bridge option if needed, while his veteran presence aids in mentoring younger players and maintaining stability.

Advertisement

The trade cost Philadelphia only a distant seventh-round pick, underscoring Dalton’s market value as a low-risk, high-floor addition. Analysts graded the deal positively for both sides, noting Dalton’s fit in a competitive NFC East environment.

5. At 38, Dalton continues defying age with durability and adaptability

Entering his 16th season, Dalton remains one of the league’s most durable quarterbacks, rarely missing time due to injury. His career longevity stems from smart decision-making, pocket presence and adaptability across schemes — from the Bengals’ balanced attack to the run-heavy approaches in Dallas and New Orleans, and mentoring duties in Carolina.

Despite never reaching a Super Bowl, Dalton’s consistency — including multiple 3,000-yard seasons and playoff berths — earns respect league-wide. The Eagles trade extends his career, offering a chance for late-stage impact in a contender setting.

Advertisement

As Dalton prepares for Philadelphia, his journey from second-round pick to respected veteran underscores resilience in a quarterback-volatile league. The low-key move highlights his enduring value as a pro’s pro ready for whatever role awaits.

Continue Reading

Business

Form 13G Zeta Network Group For: 18 March

Published

on


Form 13G Zeta Network Group For: 18 March

Continue Reading

Business

Selling Sheffield Wednesday

Published

on

Selling Sheffield Wednesday

BBC Sport looks at one of England’s most famous football clubs’ fight for survival.

Continue Reading

Business

Bentley workers 'shocked and angry' at job cuts

Published

on

Bentley workers 'shocked and angry' at job cuts

A union says the announcement came as a blow to employees with up to 275 positions at risk.

Continue Reading

Business

Icotyde psoriasis pill from J&J to rival Tremfya Skyrizi IL-23 shots

Published

on

Icotyde psoriasis pill from J&J to rival Tremfya Skyrizi IL-23 shots

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025.

Kyle Grillot | Bloomberg | Getty Images

Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.

Advertisement

The FDA approved the pill, Icotyde, to treat moderate to severe plaque psoriasis, an autoimmune condition that causes rough patches of skin. Patients typically start treatment with topical medications.

If those don’t work, they advance to pills or shots. J&J sees Icotyde becoming the first-line systematic treatment for psoriasis, in between topicals and shots.

Drugmakers have been developing more advanced medicines than standard topicals, turning psoriasis into a highly competitive space. Icotyde targets the same IL-23 receptor as best-selling shots like J&J’s Tremfya and AbbVie‘s Skyrizi, giving patients an oral alternative to some of the most advanced — and most expensive — drugs on the market.

“To be able to to be able to have something that is relatively simple, that offers that level of clearance, trusted safety profile, and in a simple pill, we think is going to be revolutionary,” said Jennifer Taubert, chairman of J&J Innovative Medicine.

Advertisement

J&J estimates about 8 million people in the U.S. have plaque psoriasis, and that 75% of people don’t advance from topicals to shots because of reasons like fearing needles. Taubert sees Icotyde appealing to those patients.

“We believe having the type of profile that Icotyde has in a simple, once-daily oral pill, we think it’s going to be an absolute game changer for patients,” Taubert said.

J&J hasn’t announced how much Icotyde will cost beyond saying the company will help people pay for the medicine. Rival shots Tremfya and Skyrizi cost around $100,000 a year.

J&J sees peak annual sales of Icotyde exceeding $5 billion once it’s approved for other autoimmune conditions. It’s testing the drug for psoriatic arthritis, ulcerative colitis and Crohn’s disease.

Advertisement

Shares of J&J slid one-quarter of a percent Wednesday while shares of Skyrizi-maker AbbVie fell more than 4%. Protagonist Therapeutics, a biotech company that developed Icotyde with J&J, was trading about flat.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Continue Reading

Business

Brightstar Lottery stock hits 52-week low at 12.6 USD

Published

on


Brightstar Lottery stock hits 52-week low at 12.6 USD

Continue Reading

Business

Stocks Can’t Recover While Oil Prices Surge. Why the Fed’s Unlikely to Help.

Published

on

Stocks Can’t Recover While Oil Prices Surge. Why the Fed’s Unlikely to Help.

Stocks Can’t Recover While Oil Prices Surge. Why the Fed’s Unlikely to Help.

Continue Reading

Business

US holds interest rates as Iran war triggers oil shock

Published

on

US holds interest rates as Iran war triggers oil shock

The US central bank is moving cautiously, despite pressure from the president to cut interest rates.

Continue Reading

Business

Big Tech’s Huge Conglomerate Premium

Published

on

Big Tech’s Huge Conglomerate Premium

Big Tech’s Huge Conglomerate Premium

Continue Reading

Business

Datassential reveals top emerging foodservice chains

Published

on

Datassential reveals top emerging foodservice chains

Top chains specialized in focused concepts and tapped into trending flavors.

Continue Reading

Trending

Copyright © 2025